Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 3
1972 2
1973 1
1975 1
1976 3
1994 1
1996 1
1997 2
1998 2
1999 2
2001 1
2002 4
2003 3
2004 4
2005 5
2006 6
2007 2
2008 1
2010 1
2013 1
2015 1
2016 4
2017 1
2018 3
2019 4
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
The CYTONOX trial.
Gade C, Mikus G, Christensen HR, Dalhoff KP, Holm JC, Holst H. Gade C, et al. Dan Med J. 2016 May;63(5):A5226. Dan Med J. 2016. PMID: 27127017 Free article. Clinical Trial.
The primary end points are: in vivo clearance of CYP3A4, CYP2E1 and CYP1A2 substrates, which will be defined by using well-tested probes; midazolam, chlorzoxazone and caffeine. Each of the probes will be administered as a single dose. ...
The primary end points are: in vivo clearance of CYP3A4, CYP2E1 and CYP1A2 substrates, which will be defined by using well-tested probes; mi …
Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.
Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE. Hohmann N, et al. Br J Clin Pharmacol. 2019 Oct;85(10):2310-2320. doi: 10.1111/bcp.14040. Epub 2019 Aug 9. Br J Clin Pharmacol. 2019. PMID: 31222796 Free PMC article. Clinical Trial.
AIMS: Chlorzoxazone is the paradigm marker substrate for CYP2E1 phenotyping in vivo. ...Microdosing chlorzoxazone could circumvent this problem. METHOD: We enrolled 12 healthy volunteers in a trial investigating the dose-exposure relationship of single ascending …
AIMS: Chlorzoxazone is the paradigm marker substrate for CYP2E1 phenotyping in vivo. ...Microdosing chlorzoxazone could circum …
Effect of Clomethiazole Vs. Clorazepate on Hepatic Fat and Serum Transaminase Activities in Alcohol-Associated Liver Disease: Results from a Randomized, Controlled Phase II Clinical Trial.
Hohmann N, Schröder F, Moreira B, Teng H, Burhenne J, Bruckner T, Mueller S, Haefeli WE, Seitz HK. Hohmann N, et al. Alcohol Alcohol. 2023 Mar 10;58(2):134-141. doi: 10.1093/alcalc/agac068. Alcohol Alcohol. 2023. PMID: 36562601 Clinical Trial.
Sixty patients were randomly assigned to ADT with either CMZ or clorazepate (CZP) for 7-10 days in a 1:1 ratio. The chlorzoxazone test of CYP2E1 activity was performed at enrolment and at 2 points during the study. ...
Sixty patients were randomly assigned to ADT with either CMZ or clorazepate (CZP) for 7-10 days in a 1:1 ratio. The chlorzoxazone tes …
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism.
Benowitz NL, Peng M, Jacob P 3rd. Benowitz NL, et al. Clin Pharmacol Ther. 2003 Nov;74(5):468-74. doi: 10.1016/j.clpt.2003.07.001. Clin Pharmacol Ther. 2003. PMID: 14586387 Clinical Trial.
Considerable individual variability was noted in the extent of induction of metabolism by cigarette smoking, particularly as it affects chlorzoxazone (change in oral clearance ranged from -10% to +71%). Carbon monoxide had no effect on chlorzoxazone or caffeine meta …
Considerable individual variability was noted in the extent of induction of metabolism by cigarette smoking, particularly as it affects c
Variability in the disposition of chlorzoxazone.
de Vries JD, Salphati L, Horie S, Becker CE, Hoener BA. de Vries JD, et al. Biopharm Drug Dispos. 1994 Oct;15(7):587-97. doi: 10.1002/bdd.2510150706. Biopharm Drug Dispos. 1994. PMID: 7849234 Clinical Trial.
Chlorzoxazone is 6-hydroxylated by cytochrome P450 2E1 (CYP 2E1), which bioactivates many toxic and carcinogenic molecules. Seventeen volunteers of varying age, ethnicity, and gender received a 250 mg tablet of chlorzoxazone and their blood and urine were sampled fr
Chlorzoxazone is 6-hydroxylated by cytochrome P450 2E1 (CYP 2E1), which bioactivates many toxic and carcinogenic molecules. Seventeen
Higher chlorzoxazone clearance in obese children compared with nonobese peers.
Gade C, Dalhoff K, Petersen TS, Riis T, Schmeltz C, Chabanova E, Christensen HR, Mikus G, Burhenne J, Holm JC, Holst H. Gade C, et al. Br J Clin Pharmacol. 2018 Aug;84(8):1738-1747. doi: 10.1111/bcp.13602. Epub 2018 Jun 3. Br J Clin Pharmacol. 2018. PMID: 29618168 Free PMC article. Clinical Trial.
METHODS: Seventy children were divided into groups by body mass index (BMI) standard deviation score (SDS). All children received 250 mg oral chlorzoxazone (CLZ) as probe for CYP2E1 activity. Thirteen blood samples and 20-h urine samples were collected per participant. ...
METHODS: Seventy children were divided into groups by body mass index (BMI) standard deviation score (SDS). All children received 250 mg ora …
Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF. Nolin TD, et al. Clin Pharmacol Ther. 2003 Dec;74(6):555-68. doi: 10.1016/j.clpt.2003.09.003. Clin Pharmacol Ther. 2003. PMID: 14663458 Clinical Trial.
OBJECTIVE: The purposes of this study were (1) to describe the disposition of chlorzoxazone and 6-hydroxychlorzoxazone in patients with kidney disease, (2) to develop a population pharmacokinetic model including covariates that may influence the pharmacokinetic variability …
OBJECTIVE: The purposes of this study were (1) to describe the disposition of chlorzoxazone and 6-hydroxychlorzoxazone in patients wi …
Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
Trousil S, Lee P, Edwards RJ, Maslen L, Lozan-Kuehne JP, Ramaswami R, Aboagye EO, Clarke S, Liddle C, Sharma R. Trousil S, et al. Br J Pharmacol. 2019 Sep;176(18):3712-3722. doi: 10.1111/bph.14776. Epub 2019 Aug 5. Br J Pharmacol. 2019. PMID: 31236938 Free PMC article. Clinical Trial.
EXPERIMENTAL APPROACH: Patients with advanced stage ovarian cancer and healthy volunteers were recruited. Participants received caffeine, chlorzoxazone, dextromethorphan, and omeprazole as in vivo probes for CYP1A2, CYP2E1, CYP2D6, CYP3A, and CYP2C19. ...KEY RESULTS: CYP2E …
EXPERIMENTAL APPROACH: Patients with advanced stage ovarian cancer and healthy volunteers were recruited. Participants received caffeine, …
The effect of chlorzoxazone on acute pain after spine surgery. A randomized, blinded trial.
Nielsen RV, Fomsgaard JS, Siegel H, Martusevicius R, Mathiesen O, Dahl JB. Nielsen RV, et al. Acta Anaesthesiol Scand. 2016 Sep;60(8):1152-60. doi: 10.1111/aas.12754. Epub 2016 Jun 16. Acta Anaesthesiol Scand. 2016. PMID: 27306492 Clinical Trial.
Chlorzoxazone for low back pain is currently not advised due to the lack of placebo-controlled trials. We explored the effect of chlorzoxazone on acute pain after spine surgery. METHODS: One hundred and ten patients were randomly assigned to 500 mg oral chlorzoxa
Chlorzoxazone for low back pain is currently not advised due to the lack of placebo-controlled trials. We explored the effect of c
Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers.
Huledal G, Olsson B, Önnestam K, Dalén P, Lindqvist D, Kruse M, Bröijersén A. Huledal G, et al. Eur J Clin Pharmacol. 2019 Mar;75(3):313-320. doi: 10.1007/s00228-018-2581-7. Epub 2018 Nov 15. Eur J Clin Pharmacol. 2019. PMID: 30443705 Clinical Trial.
METHODS: This was an open-label, nonrandomized, two-arm, phase 1 study (EudraCT: 2016-004297-17) in healthy volunteers. The substrates (tolbutamide, metoprolol, and chlorzoxazone for the respective CYPs and furosemide for the OATs) were administered as single doses, before …
METHODS: This was an open-label, nonrandomized, two-arm, phase 1 study (EudraCT: 2016-004297-17) in healthy volunteers. The substrates (tolb …
58 results